Nilandron (Concordia Pharmaceuticals Inc.)
Welcome to the PulseAid listing for the Nilandron drug offered from Concordia Pharmaceuticals Inc.. This Androgen Receptor Antagonists [MoA],Androgen Receptor Inhibitor [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Concordia Pharmaceuticals Inc. |
NON-PROPRIETARY NAME: | Nilutamide |
SUBSTANCE NAME: | NILUTAMIDE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Androgen Receptor Antagonists [MoA],Androgen Receptor Inhibitor [EPC] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2013-07-15 |
END MARKETING DATE: | 0000-00-00 |
Nilandron HUMAN PRESCRIPTION DRUG Details:
Item Description | Nilandron from Concordia Pharmaceuticals Inc. |
LABELER NAME: | Concordia Pharmaceuticals Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 150(mg/1) |
START MARKETING DATE: | 2013-07-15 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 59212-111_648e10b6-b7f1-4be0-9fdc-e925e9fbba65 |
PRODUCT NDC: | 59212-111 |
APPLICATION NUMBER: | NDA020169 |
Other NILUTAMIDE Pharmaceutical Manufacturers / Labelers: